ACMA Announces New Investment and Expansion in the Asian Life Sciences Market

By AIT News Desk On Jun 10, 2020

The ACMA will invest heavily in Asia to increase awareness of the importance of professional standards in the pharmaceutical market for all medical affairs and medical science liaison professionals

The Accreditation Council for Medical Affairs (ACMA) announced its new head of business for Asia, Yue Hu. The appointment of this new position is part of a larger effort by the ACMA, which will invest several m************** into growing its footprint in the Asia market. The ACMA has also established a leadership council to represent the interests of medical affairs professionals in China, India, Indonesia, Japan, Malaysia, the Philippines, Singapore, South Korea, Taiwan, and Vietnam along with other Asian countries.

“The pharmaceutical market has grown significantly in Asia and we are now seeing a rapid increase in the numbers of companies hiring medical science liaisons (MSLs) and medical affairs professionals,” said ACMA Founder and CEO, Dr. William Soliman. “These new teams need to set their bar for excellence high to deliver value to their companies, their key opinion leader stakeholders and patients.”

The ACMA developed the first board certification ever for MSLs and medical affairs professionals in 2015 and its Board Certified Medical Affairs Specialist (BCMAS) program is now considered the industry standard in the pharma world. “The importance of establishing global professional standards in the pharmaceutical industry for medical affairs professionals cannot be overstated,” said Eric Bouilloux, Associate Vice President Scientific Affairs – Operations, Accord Healthcare. “Other professional bodies across the healthcare world all have minimum standards of excellence. Medical affairs and MSL professionals are no different. Critically, with BCMAS we are also distinguishing ourselves from pharma sales professionals.”